New picosecond laser treats pigmentary disorders in darker skin types


The new 730-nm picosecond laser demonstrates strong efficacy and safety in darker skin types for treatment of endogenous pigmentary disorders, according to a recent case study.

A case report published The American Society for Laser Medicine and Surgery shows the new 730-nm picosecond laser to have strong efficacy and safety in treating endogenous pigmentary disorders on darker skin types.

RELATED: Combination treatment outshines oral treatment alone for melasma

Typically, picosecond lasers have been used for tattoo removal but are gaining traction as a novel treatment for pigmentary disorders, a market which has previously been dominated by quality-switched nanosecond lasers. The 730-nm picosecond laser was specifically designed to target melanocytes and melanin.1

The study examines two Korean patients with III-IV Fitzpatrick skin types, as well as melasma, freckles and lentigines who were treated with 730‐nm Ti:Sapphire picosecond laser (Picoway, Syneron Candela Corp) with a pulse duration of 240 picoseconds.2

Both researchers saw significant pigmentary reduction and with one treatment session, which was well tolerated without topical anesthesia in both patients. In the 6-week follow-up, there were no observed post-inflammatory hyperpigmentation/repigmentation in either patient.1

MORE: Melasma in the male patient

“The new commercial 730 nm laser-pumped laser may be effective and safe in treating pigmentary disorders in darker-skinned patients,” says Sang Ju Lee, M.D., Ph.D., study investigator.

More information about the case study can be found here.


1. Green, E. (2020, June 17). A new picosecond laser for the treatment of pigmentary disorders in darker-skinned patients. Retrieved July 30, 2020, from

2. Lee, S. J., Han, H. S., Hong, J. K., Park, K. Y., & Seo, S. J. (2020). Successful Treatment of Pigmentary Disorders in Asians With a Novel 730‐nm Picosecond Laser. Lasers in Surgery and Medicine. doi:10.1002/lsm.23261

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.